HDL as a contrast agent for medical imaging

Future Lipidology

Volumn 4, Issue 4, 2009, Pages 493-500

  Cormode, David P ^a   Frias, Juan C ^a   Ma, Yanqing ^b   Chen, Wei ^a   Skajaa, Torjus ^a,c   Briley Saebo, Karen ^a   Barazza, Alessandra ^a,b   Williams, Kevin Jon ^d   Mulder, Willem J M ^a   Fayad, Zahi A ^a   Fisher, Edward A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c AARHUS UNIVERSITY   (Denmark)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Contrast agent; HDL; Lipoproteins; Medical imaging; MRI; Nanoparticle

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NANOCRYSTAL; NANOPARTICLE; PENTETIC ACID;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL DENSITY; CELL SPECIFICITY; CHEMICAL MODIFICATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG TARGETING; FLUORESCENCE ANALYSIS; FLUORESCENCE IMAGING; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; MACROPHAGE; NANOTECHNOLOGY; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

EID: 69549115119     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/CLP.09.38     Document Type: Review

References (47)

1. Mulder WJM, Cormode DP, Hak S, Lobatto ME, Silvera S, Fayad ZA: Multimodality nanotracers for cardiovascular applications. Nat. Clin. Pract. Cardiovasc. Med. 5, S103-S111 (2008).
2. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis through the arterial tree. Arterioscl. Thromb. 14, 133-140 (1994).
3. Fayad ZA, Fallon JT, Shinnar M et al.: Noninvasive in vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation 98, 1541-1547 (1998).
4. Trogan E, Fayad ZA, Itskovich VV et al.: Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 24, 1714-1719 (2004).
5. Choudhury RP, Fayad ZA, Aguinaldo JG et al.: Serial, noninvasive, in vivo magnetic resonance microscopy detects the development of atherosclerosis in apolipoprotein E-deficient mice and its progression by arterial wall remodeling. J. Magn. Reson. Imaging 17, 184-189 (2003).
6. Shamir R, Johnson WJ, Morlock-Fitzpatrick K et al.: Pancreatic carboxyl ester lipase: a circulating enzyme that modifies normal and oxidized lipoproteins in vitro. J. Clin. Invest. 97, 1696-1704 (1996).
7. Lusis AJ: Atherosclerosis. Nature 407, 233-241 (2000).
8. 125I-BSA. Pathobiology 69, 225-229 (2001).
9. Frias JC, Williams KJ, Fisher EA, Fayad ZA: Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126, 16316-16317 (2004).
10. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA: Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano. Lett. 6, 2220-2224 (2006).
11. Briley-Saebo KC, Geninatti Crich S, Cormode DP et al.: High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents. J. Phys. Chem. B. 113, 6283-6289 (2009).
12. Gianolio E, Giovenzana GB, Longo D, Longo I, Menegotto I, Aime S: Relaxometric and modelling studies of the binding of a lipophilic Gd-AAZTA complex to fatted and defatted human serum albumin. Chem. Eur. J. 13, 5785-5797 (2007).
13. Chen W, Vucic E, Leupold E et al.: Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol. Imaging 3, 233-242 (2008).
14. Sauer I, Dunay IR, Weisgraber K, Bienert M, Dathe M: An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry 44, 2021-2029 (2005).
15. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM: Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat. Clin. Pract. Cardiovasc. Med. 3, 540-547 (2006).
16. Frank PG, Marcel YL: Apolipoprotein A-I: structure-function relationships. J. Lipid Res. 41, 853-872 (2000).
17. Anantharamaiah GM, Jones JL, Brouillette CG et al.: Studies of synthetic peptide analogs of the amphipathic helix. J. Biol. Chem. 260, 10248-10255 (1985).
18. Davidson WS, Lund-Katz S, Johnson WJ et al.: The influence of apolipoprotein structure on the efflux of cellular free cholesterol to high density lipoprotein. J. Biol. Chem. 269, 22975-22982 (1994).
19. Anantharamaiah GM: Synthetic peptide analogs of apolipoproteins. Method. Enzymol. 128, 627-647 (1986).
20. Tang C, Vaughan AM, Anantharamaiah GM, Oram JF: Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J. Lipid Res. 47, 107-114 (2006).
21. Cormode DP, Briley-Saebo KC, Mulder WJM et al.: An apoA-I mimetic peptide HDL-based MRI contrast agent for atherosclerotic plaque composition detection. Small 4, 1437-1444 (2008).
22. Cormode DP, Chandrasekar R, Delshad A et al.: Comparison of synthetic HDL contrast agents for MR imaging of atherosclerosis. Bioconjugate Chem. 20, 937-943 (2009).
23. Rensen PCN, de Vrueh RLA, Kuiper J, Bijsterbosch MK, Biessen EAL, van Berkel TJC: Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. 47, 251-276 (2001).
24. Cormode DP, Skajaa T, van Schooneveld MM et al.: Nanocrystal core high-density lipoproteins: a multimodal molecular imaging contrast agent platform. Nano. Lett. 8, 3715-3723 (2008).
25. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM: Gold nanoparticles: a new x-ray contrast agent. Brit. J. Radiol. 79, 248-253 (2006).
26. Bulte JWM, Kraitchman DL: Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 17, 484-499 (2004).
27. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H: Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 4, 435-446 (2005).
28. Frias JC, Lipinski MJ, Lipinski SE, Albelda MT: Modified lipoproteins as contrast agents for imaging of atherosclerosis. Contrast Media Mol. Imaging 2, 16-23 (2007).
29. Sinzinger H, Bergmann H, Kaliman J, Angelberger P: Imaging of human atherosclerosis lesions using I-123 low-density-lipoprotein. Eur. J. Nucl. Med. 12, 291-292 (1986).
30. Rosen JM, Butler SP, Meinken GE et al.: Indium-111-labeled LDL: a potential agent for imaging atherosclerotic disease and lipoprotein biodistribution. J. Nucl. Med. 31, 343-350 (1990).
31. 99mTechnetium-labeled low density lipoprotein uptake by tendon xanthomas in hypercholesterolemic patients. Arteriosclerosis 10, 256-262 (1990).
32. Mitsumori LM, Ricks JL, Rosenfeld ME, Schmiedl UP, Yuan C: Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease. Int. J. Cardiovasc. Imaging 20, 561-567 (2004).
33. Li H, Gray BD, Corbin IR et al.: MR and fluorescent imaging of low-density lipoprotein receptors. Acad. Radiol. 11, 1251-1259 (2004).
34. Geninatti Crich S, Lanzardo S, Alberti D et al.: Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low-density lipoprotein particles. Neoplasia 9, 1046-1056 (2007).
35. Corbin IR, Li H, Chen J et al.: Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia 8, 488-498 (2006).
36. Chen J, Corbin IR, Li H, Cao W, Glickson JD, Zheng G: Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo. J. Am. Chem. Soc. 129, 5798-5799 (2007).
37. Gordon DJ, Rifkind BM: High-density lipoprotein - the clinical implications of recent studies. N. Engl. J. Med. 321, 1311-1316 (1989).
38. Jonas A: Reconstitution of high-density lipoproteins. Method. Enzymol. 128, 553-582 (1986).
39. Rye K-A, Barter PJ: Antiinflammatory actions of HDL: a new insight. Arterioscler. Thromb. Vasc. Biol. 28, 1890-1891 (2008).
40. Jaffer FA, Libby P, Weissleder R: Molecular imaging of cardiovascular disease. Circulation 116, 1052-1061 (2007).
41. 18F-FDG PET: carotid, iliac and femoral uptake reproducibility, quantification methods, and recommendations. J. Nucl. Med. 49, 871-878 (2008).
42. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ: A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest. Radiol. 43, 65-75 (2008).
43. Choi HS, Liu W, Misra P et al.: Renal clearance of quantum dots. Nat. Biotech. 25, 1165-1170 (2007).
44. Korolenko TA, Klishevich MS, Cherkanova MS et al.: In vivo effect of selective macrophage suppression on the development of intrahepatic cholestasis in mice. Bull. Exp. Biol. Med. 146, 396-400 (2008).
45. Ide M, Kuwamura M, Kotani T, Sawamoto O, Yamate J: Effects of gadolinium chloride (GdCl3) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J. Comp. Pathol. 133, 92-102 (2005).
46. Trivedi RA, U-King-Im JM, Graves MJ et al.: In vivo detection of macrophages in human carotid atheroma - temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 35, 1631-1635 (2004).
47. Zheng G, Chen J, Li H, Glickson JD: Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc. Natl Acad. Sci. USA. 102, 17757-17762 (2005).